Mar 11th 2013 - Edison Investment Research today published a report on Mast Therapeutics entitled "Expanding Horizons For MST-188". In summary, the report says:
Mast Therapeutics, previously Adventrx Pharmaceuticals, is seeking to broaden the therapeutic potential of its lead candidate MST-188 (ANX-188) beyond sickle cell disease (SCD), with a Phase II study in acute limb ischaemia (ALI) planned for late-2013 or early-2014. ALI study results in 2015 should coincide with headline data from the ongoing pivotal Phase III (EPIC) trial of MST-188 in SCD – positive outcomes in both settings would present a compelling partnering case for MST-188. Adding the ALI opportunity increases our overall valuation of Mast to $148m, or $2.70 per share.
Edison Investment Research is a leading international investment research company. It has won industry recognition, with awards both in the UK and internationally. The team of 95 includes over 60 analysts supported by a department of supervisory analysts, editors and assistants. Edison writes on more than 400 companies across every sector and works directly with corporates, fund managers, investment banks, brokers and other advisers. Edison’s research is read by institutional investors, alternative funds and wealth managers in more than 100 countries. Edison, founded in 2003, has offices in London, New York and Sydney and is authorised and regulated by the Financial Services Authority (www.fsa.gov.uk/register/firmBasicDetails.do?sid=181584). more »